Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM95A4Z)

Drug Name

[125I]APNEA Drug Info

Synonyms

CHEMBL326958; 2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; [3H]N6-2-(4-Aminophenyl)ethyladenosine; AC1L1I2P; AC1Q4Y3F; Lopac0_000118; GTPL417; GTPL462; ChEMBL_198532; SCHEMBL16585344; HMS3260G18; n-[2-(4-aminophenyl)ethyl]-9-pentofuranosyl-9h-purin-6-amine; Tox21_500118; BDBM50037785; LP00118; CCG-204213; NCGC00260803-01; NCGC00093612-03; NCGC00015017-04; NCGC00093612-02; NCGC00093612-01; NCGC00015017-05; NCGC00015017-03; NCGC00015017-02; [3H]N6-2-(4-aminophenyl)ethyladenosine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 4397
TTD Drug ID: DM95A4Z

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[3]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[4]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[5]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[6]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[7]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[8]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[9]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[10]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[6]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 462).
2	Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7432-6.
3	A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
4	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
5	Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
6	2011 Pipeline of Can-Fite BioPharm.
7	Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
8	Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
9	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
10	Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.